↓ Skip to main content

Dove Medical Press

Article Metrics

Highly absorptive curcumin reduces serum atherosclerotic low-density lipoprotein levels in patients with mild COPD

Overview of attention for article published in International Journal of Chronic Obstructive Pulmonary Disease, August 2016
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age (60th percentile)
  • Above-average Attention Score compared to outputs of the same age and source (52nd percentile)

Mentioned by

twitter
4 tweeters
facebook
1 Facebook page

Citations

dimensions_citation
25 Dimensions

Readers on

mendeley
34 Mendeley
Title
Highly absorptive curcumin reduces serum atherosclerotic low-density lipoprotein levels in patients with mild COPD
Published in
International Journal of Chronic Obstructive Pulmonary Disease, August 2016
DOI 10.2147/copd.s104490
Pubmed ID
Authors

Tatsuya Morimoto, Masafumi Funamoto, Yoichi Sunagawa, Yasufumi Katanasaka, Yusuke Miyazaki, Atsushi Imaizumi, Hideaki Kakeya, Hajime Yamakage, Noriko Satoh-Asahara, Maki Komiyama, Hiromichi Wada, Koji Hasegawa

Abstract

COPD is mainly caused by tobacco smoking and is associated with a high frequency of coronary artery disease. There is growing recognition that the inflammation in COPD is not only confined to the lungs but also involves the systemic circulation and can impact nonpulmonary organs, including blood vessels. α1-antitrypsin-low-density lipoprotein (AT-LDL) complex is an oxidatively modified LDL that accelerates atherosclerosis. Curcumin, one of the best-investigated natural products, is a powerful antioxidant. However, the effects of curcumin on AT-LDL remain unknown. We hypothesized that Theracurmin(®), a highly absorptive curcumin with improved bioavailability using a drug delivery system, ameliorates the inflammatory status in subjects with mild COPD. This is a randomized, double-blind, parallel-group study. Subjects with stages I-II COPD according to the Japanese Respiratory Society criteria were randomly assigned to receive 90 mg Theracurmin(®) or placebo twice a day for 24 weeks, and changes in inflammatory parameters were evaluated. There were no differences between the Theracurmin(®) and placebo groups in terms of age, male/female ratio, or body mass index in 39 evaluable subjects. The percent changes in blood pressure and hemoglobin A1c and LDL-cholesterol, triglyceride, or high-density lipoprotein-cholesterol levels after treatment were similar for the two groups. However, the percent change in the AT-LDL level was significantly (P=0.020) lower in the Theracurmin(®) group compared with the placebo group. Theracurmin(®) reduced levels of atherosclerotic AT-LDL, which may lead to the prevention of future cardiovascular events in mild COPD subjects.

Twitter Demographics

The data shown below were collected from the profiles of 4 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 34 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 34 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 6 18%
Researcher 6 18%
Other 4 12%
Student > Master 4 12%
Lecturer 2 6%
Other 6 18%
Unknown 6 18%
Readers by discipline Count As %
Medicine and Dentistry 14 41%
Agricultural and Biological Sciences 4 12%
Nursing and Health Professions 2 6%
Chemical Engineering 1 3%
Biochemistry, Genetics and Molecular Biology 1 3%
Other 4 12%
Unknown 8 24%

Attention Score in Context

This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 09 August 2017.
All research outputs
#5,978,181
of 11,590,856 outputs
Outputs from International Journal of Chronic Obstructive Pulmonary Disease
#541
of 1,355 outputs
Outputs of similar age
#98,822
of 258,109 outputs
Outputs of similar age from International Journal of Chronic Obstructive Pulmonary Disease
#44
of 98 outputs
Altmetric has tracked 11,590,856 research outputs across all sources so far. This one is in the 47th percentile – i.e., 47% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,355 research outputs from this source. They receive a mean Attention Score of 4.7. This one has gotten more attention than average, scoring higher than 58% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 258,109 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 60% of its contemporaries.
We're also able to compare this research output to 98 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 52% of its contemporaries.